Arbyn et al 2006: Clinical applications of HPV testing: a summary of meta-analyses.
Bartholomew et al 2011 Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples.
Belinson et al 2011 A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study.
Bory et al 2002 Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women.
Bulk et al 2007 Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulkmans et al 2007 Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.
Castle et al 2009 Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping.
Castle et al 2011 Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Carozzi et al 2011Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
Clad et al 2011 Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
Clavel et al 1998 Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions.
Cuzick et al. 2006 Overview of the European and North American studies on HPV testing in primary cervical cancer screening.
Cuzick et al 2010 Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears.
Dalstein et al 2009 Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Day et al 2009 Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study.
Didelot et al 2011 Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes.
Dockter et al 2009 Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.
Einstein et al 2010 Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
Halfon et al 2010 Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection.
Harvey et al. 2009 The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection.
Heideman et al 2011 Clinical validation of the cobas 4800 HPV test for cervical screening purposes.
Hesselink et al 2010 Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.
Huang et al 2009 Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.
Iftner and Villa 2003 Chapter 12: Human Papillomavirus technologies.
Jamison et al 2009 The evaluation of human papillomavirus genotyping in cervical liquid-based cytology specimens; using the Roche Linear Array HPV genotyping assay.
Johnson et al 2008 A comparison of two methods to determine the presence of high-risk HPV cervical infections.
Kaliterna et al 2009 Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens.
Mayrand et al 2007 Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.
Meijer et al. 2009 Validation of high-risk HPV tests for primary cervical screening.
Meijer et al 2009 Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
Monsonego et al 2011 Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Poljak et al 2011Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Quigley et al 2011 Rate of detection of high-risk HPV with two assays in women ≥ 30 years of age.
Quint et al 2006 Results of the First World Health Organization International Collaborative Study of Detection of Human Papillomavirus DNA.
Ratnam et al 2011 Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
Ronco et al 2006 Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial.
Ronco et al 2006 Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco et al 2009 Cervical screening according to age and HPV status.
Ronco et al 2010 Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
Schopp et al 2010 Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test.
Stoler et al 2011 High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.
Literaturliste downloaden (PDF)